Are there clinical trials of MOTS-c administration?

No established registered interventional trials of administration. The human literature measures endogenous concentrations rather than testing the peptide as an intervention.

Which paper should I read first?

The 2015 Cell Metabolism discovery paper, PMID 25738459. It establishes the peptide, its origin and its mechanism, and everything since references it.

Is 250 papers a large literature?

Modest. For comparison, well-established compounds accumulate thousands. It reflects a field roughly a decade old and still mostly preclinical.

MOTS-c (Mitochondrial Peptide)

MOTS-c in the Published Literature

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

MOTS-c appears in roughly 250 indexed PubMed records since 2015. Three papers anchor the field: the 2015 discovery in Cell Metabolism, the 2018 nuclear translocation finding, and the 2021 exercise study in Nature Communications. The literature is overwhelmingly preclinical, with human work largely observational.

Key facts

Indexed PubMed records: ~250
First publication: 3 March 2015
Discovery paper: PMID 25738459, Cell Metabolism
Nuclear signalling: PMID 29983246, Cell Metabolism 2018
Exercise study: PMID 33473109, Nature Communications 2021
Evidence base: Predominantly cell and rodent models
Human data: Largely observational
Registered clinical trials: None established for administration

The three anchor papers

The 2015 Cell Metabolism paper by Lee, Zeng, Drew and colleagues identified the peptide and reported its metabolic effects in mouse models. The 2018 Cell Metabolism paper by Kim, Son and Benayoun reported nuclear translocation under metabolic stress. The 2021 Nature Communications paper by Reynolds, Lai, Woodhead and colleagues reported exercise induction, with roughly 12-fold skeletal-muscle and 1.6-fold circulating increases in humans. Nearly everything else in the field builds on one of these three.

What kind of evidence this is

The great majority of the literature is preclinical: cultured cells and rodent models. Human involvement has largely taken the form of measuring endogenous concentrations and correlating them with age, fitness or metabolic state. That is a different category of evidence from an interventional trial, and the distinction governs what any of it can support.

Research material referenced

MOTS-C 10mg — third-party HPLC tested

View — £24.99

Why correlation is the ceiling for the human data

Observing that circulating MOTS-c is lower in older or less metabolically healthy people establishes an association. It does not establish direction — the concentration could be a consequence of mitochondrial state rather than a cause of anything — and it certainly does not establish what administration would do. This is the inference the secondary literature most commonly overreaches on.

Where the newer work is going

More recent publications have examined mitochondrial respiration in disease models, including work on the diabetic heart, and on muscle mitochondrial bioenergetics in a PGC-1α/AMPK-dependent manner. These extend the mechanistic picture within the same preclinical frame rather than moving the evidence into a new category.

How to search it yourself

PubMed indexes the field under 'MOTS-c'. Filtering by publication type separates reviews from primary research, and checking the model organism in the abstract is the fastest way to establish what kind of evidence a given paper actually offers. Reviews are useful for orientation but inherit the limitations of what they summarise.

Extended research context

The MOTS-c (Mitochondrial Peptide) deep dive

Deep dive: why a peptide encoded in mitochondrial DNA is unusual

The human mitochondrial genome is 16,569 base pairs encoding 37 genes, and was considered fully characterised by the 1980s: thirteen respiratory-chain proteins, twenty-two transfer RNAs, two ribosomal RNAs. MOTS-c is encoded by a short open reading frame nested inside the 12S rRNA gene — sequence already annotated as doing something else, which is exactly why it went unnoticed. Humanin, found in 2001 inside the 16S rRNA gene, established that the genome held more than its annotation suggested; MOTS-c was found in 2015 by looking deliberately. The implication is that the mitochondrion encodes and releases signalling molecules of its own, rather than only executing instructions sent from the nucleus.

Deep dive: AMPK activation without touching AMPK

AMPK is normally activated when AMP and ADP bind its gamma subunit, making it a direct sensor of the AMP-to-ATP ratio. MOTS-c does not raise that ratio and does not bind the kinase. It inhibits the folate cycle, the one-carbon pathway feeding de novo purine biosynthesis, and the intermediate AICAR accumulates as a result. AICAR is an AMP mimetic — phosphorylated to ZMP, it binds the same regulatory site AMP occupies. So the peptide reaches a cytosolic energy sensor through one-carbon metabolism and a diffusible small molecule, which is a materially different architecture from a receptor-ligand interaction, and different again from metformin's inhibition of complex I.

Deep dive: reading a preclinical literature honestly

Roughly 250 indexed papers exist, and the overwhelming majority are cell and rodent studies. Where humans appear, the work is generally observational: measuring circulating concentrations and correlating them with age, fitness or metabolic state. The 2021 Nature Communications paper is the clearest example of the structure — the human arm measured MOTS-c before and after exercise, finding roughly a 12-fold rise in skeletal muscle against 1.6-fold in circulation, while the interventional work was done in mice. Two inferences the secondary literature routinely makes and the primary literature does not support: that a correlation between low concentrations and poor metabolic health establishes direction, and that a molecule which rises during exercise would reproduce exercise if administered.

Research applications

▸Study of mitochondrial-derived peptides and retrograde signalling
▸AMPK pathway research through non-canonical activation
▸One-carbon and folate-cycle metabolism models
▸Exercise physiology and mitochondrial bioenergetics research
▸Ageing biology and mitochondrial genome expression studies

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓Expect methionine oxidation as the primary degradation route (+16 Da per residue)
✓No reducing agent needed — the sequence contains no cysteine
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles
✓Check mass spectrometry for +16 and +32 satellites before relying on a batch

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Reading exercise induction as proof that administration mimics exercise

Fix: The papers report that exercise raises MOTS-c. The reverse inference is not supported and is not claimed.

✗ Treating human observational data as interventional evidence

Fix: Human work measures endogenous concentrations; administration studies were conducted in mice.

✗ Assuming MOTS-c has a cell-surface receptor like humanin

Fix: No receptor is established. Its characterised activity is intracellular.

✗ Storing reconstituted material as though it were as stable as the powder

Fix: Solution-phase material is subject to hydrolysis and oxidation; the lyophilised form is far more stable.

✗ Overlooking WADA status in athlete-adjacent research

Fix: MOTS-c is on the prohibited list; this is relevant to any research context involving competitors.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Are there clinical trials of MOTS-c administration?: No established registered interventional trials of administration. The human literature measures endogenous concentrations rather than testing the peptide as an intervention.
Which paper should I read first?: The 2015 Cell Metabolism discovery paper, PMID 25738459. It establishes the peptide, its origin and its mechanism, and everything since references it.
Is 250 papers a large literature?: Modest. For comparison, well-established compounds accumulate thousands. It reflects a field roughly a decade old and still mostly preclinical.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More MOTS-c (Mitochondrial Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum